Sage’s depression drug meets main goal in late-stage study By Reuters

© Reuters. FILE PHOTO: A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

(Reuters) -Sage Therapeutics Inc said on Wednesday its drug along with an antidepressant helped improve depressive symptoms after three days in a late-stage study, paving way for the drug developer to submit data for U.S. approval this year.

The company and partner Biogen Inc (NASDAQ:) said the drug, zuranolone, met the study’s secondary goal of showing an improvement in symptoms over a two-week period.

In the study among 440 participants with major depressive disorder, zuranolone along with antidepressants led to a greater reduction in symptoms, such as feelings of sadness and anxiety, from baseline compared with a combination of placebo and antidepressants.

Major depressive disorder (MDD) is a common but serious mood disorder in which people experience depressive symptoms and it affects over 16 million American adults every year.

The disorder is mainly treated with antidepressants, which could take up to six weeks to show effect and patients are typically required to continue the treatment for months after.

“What this study has done, we believe, is just substantiated that zuranolone could be a unique treatment option for patients,” said Jeff Jonas, chief innovation officer at Sage Therapeutics.

“We believe that if people can get better in days versus weeks… that’s an option that patients deserve to have.”

Sage plans to start submitting data for U.S. approval of the drug for major depressive disorder on a rolling basis early this year and is aiming to complete the application by the second half of the year.

In the study, zuranolone was generally well-tolerated with no new safety concerns, the companies said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

by : Reuters

Source link

Capital Media

Read Previous

Oil prices recoup losses as Russia-Ukraine tensions stay high By Reuters

Read Next

L’Afrique du Sud poursuit la branche locale de Huawei devant la justice pour non-respect du quota d’employés étrangers